The present invention provides pharmaceutical oral solution composition of ACE inhibitor. The oral solution composition comprises of ACE inhibitor with 5 – 9 pH and other pharmaceutical excipients having improved stability and palatability.

The present invention relates to the oral pharmaceutical composition comprising an androgen receptor inhibitor and one or more pharmaceutically acceptable excipients selected from the group comprising of fillers/vehicles, solvents/co-solvents, preservatives/antioxidants, surfactants, buffering agents, chelating agen...

Present invention relates to a pharmaceutically acceptable dosage form covering multiple drug in one capsule wherein one of these drugs is tetracycline. In the present invention current dosage form tetracycline is in tablet form filled in the capsule. Additionally this dosage may also comprise multiple release of dr...

The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.

The present invention relates to pharmaceutical composition comprising pemetrexed, a ready to use injection comprising pemetrexed. Liquid composition of pemetrexed comprises head space oxygen less than 5%, dissolved oxygen less than 2ppm and individual impurity level less than 0.2%.

ABSTRACT DRUG DELIVERY SYSTEM The present invention relates to a drug delivery system or device in the form of single unit for delivering final liquid dosage form comprising (a) a container or a bottle; (b) a cap of the container or a bottle mechanised with one or more preformed holes and one or more pins; and (c)...

The present invention is to provide modified release solid oral dosage form of topiramate or its pharmaceutically acceptable salts or derivatives which maintains an effective plasma drug concentration over an extended period of time and thereby maintain uniform and release rate of the active pharmaceutical ingredien...

The invention relates to the formulation of solid pharmaceutical compounds. Further, solid pharmaceutical composition comprising a therapeutically effective amount of teriflunomide or a pharmaceutically acceptable basic addition salt thereof and excipients.

Abstract The present invention relates to ready to dilute injectable formulations of bortezomib comprising bortezomib, non-aqueous solvents enhancing the solubility and pH modifying agent.

The present invention relates to oral solution of aripiprazole with improved solubility, stability and bioavailability of active ingredient and process for preparation of the same.

The present invention provides pharmaceutical composition of muscarinic antagonist in oral solution dosage form. The oral solution composition comprises of muscarinic antagonist with other pharmaceutical excipients such as vehicle, preservative, buffering agent, sweetener and flavouring agent. The present invention ...

ABSTRACT AN EXTENDED RELEASE MELATONIN SOLID PREPARATION The present invention is related to the extended release Melatonin preparation preferably a dry powder comprising extended release pellets of Melatonin and one or more pharmaceutically acceptable excipients selected from the group comprising of fillers, bi...

Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for admini...

Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wettin...

Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more...

METHOD FOR PREPARATION OF LIQUID ORAL COMPOSITION OF L-THYROXIN The present invention discloses a processes for the preparation of a stable liquid pharmaceutical composition comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients wherein the liquid...

The present invention relates to the liquid pharmaceutical composition comprising Imatinib and one or more pharmaceutically acceptable excipients selected from the group comprising of vehicles, preservatives, buffering agents, sweetening agents and flavouring agents or combination thereof. The present invention also...

The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavo...

The present invention provides pharmaceutical composition of immunosuppressive agentin oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming a...

PROCESSING INDUCED CRYSTAL MODIFICATION FOR IMPROVING DISSOLUTION, STABILITY AND BIOAVAILABILITY OF TELMISARTAN The present invention relates to a Meglumine salt of Telmisartan and process for the preparation thereof using melt-quench cooling technique. The Meglumine salt of Telmisartan prepared according to the ...

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The present invention relates to the pharmaceutical composition comprising Melatonin and one or more pharmaceutically acceptable excipients. The present invention also relates to the process for the preparation of the pharmaceutical composition comprising Melatonin.

Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with either parathyroid carcinoma or hyperparathyroidism. Current marketed products ar...

Liquid dosage forms of Aprepitant are not much explored. The present invention describes ready to use, oral liquid compositions of Aprepitant suitable for the patients having swallowing difficulties. The liquid compositions of the present invention are storage stable for prolonged time and can be used for the preven...

Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for admini...

ABSTRACT A MEDICAL DEVICE CONTAINING PHARMACEUTICAL COMPOSITION COMPRISING FAT REMOVING AGENT The present invention relates to a medical device containing pharmaceutical composition comprising one or more fat removing agent and one or more pharmaceutically acceptable excipient and/or carrier. ...

Commercially available soft capsules of Dutasteride (Avodart®) requires large amounts of solubilizers and permeability enhancers which results in the increase in the size of the capsule formulation. The larger capsule size poses greater potential safety issues and raises product efficacy concerns due to patient’s in...

Though oral liquid formulations of Methotrexate are advantageous as they can suitably be administered to the patients having swallowing difficulties such as pediatric patients, geriatric patients, stroke patients or patients who are unable to take solid oral therapy, they are not much explored in the prior art. Furt...

Conventional injectable formulations of Diclofenac are known to have excipients which cause irritation at the site of injection and are painful. Further, such conventional formulations also cause thrombophlebitis. Other injectable formulations of Diclofenac known in the prior art also contain excipients which are ti...

ABSTRACT LIQUID PARENTERAL COMPOSITIONS OF LEVOTHYROXINE Levothyroxine sodium for injection is particularly useful when thyroid replacement is needed on an urgent basis, for short term thyroid replacement, and/or when oral administration is not possible, such as for a patient in a state of myxedema coma. The pre...

ABSTRACT PRE-MIXED, READY TO USE VANCOMYCIN COMPOSITIONS Pre-mixed, ready-to-use injectable compositions possess certain advantages such as convenience and ease of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of me...

ABSTRACT STABLE PARENTERAL DOSAGE FORM OF PYRAZOLONE DERIVATIVE Edaravone, in the United States, is approved in the form of ready-to-use intravenous 5 solution for infusion, RADICAVA. RADICAVA injection is supplied in a polypropylene bag overwrapped with polyvinyl alcohol (PVA) secondary packaging. Edaravone is ...

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include t...

Pharmaceutical compositions comprising oil as a vehicle, a suspending agent, and a surfactant are disclosed to be used in conjunction with active pharmaceutical ingredients which are water soluble or insoluble, or which are sensitive to water but insoluble in oil. Such active pharmaceutical ingredients may include ...

ABSTRACT EDARAVONE ORAL SUSPENSION Since long, edaravone is known as a therapeutically effective agent and approved for the treatment of amyotrophic lateral sclerosis. The approved dosage forms of the edaravone include aqueous solution for intravenous administration and aqueous suspension for oral administration. ...

ABSTRACT STABLE PEPTIDE PHARMACEUTICAL COMPOSITION None of the approved & marketed desmopressin injection products is stable at room temperature. All the desmopressin injection products are advised to be stored at refrigerated conditions 2°C-8°C to prevent degradation of the active principle. It has been more than...